De Groot, AS

Desrosiers, J

Martin, W

Moise, L

Weber, C

English

PubMed

Springer - Publisher Connector

BioMed Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open AccessPoster presentation
P17-26. Effective design of T-cell driven vaccines applied to the 
GAIA HIV vaccine: advances in vaccine design based on current 
preclinical success
AS De Groot*1, L Moise1, J Desrosiers1, C Weber2 and W Martin1
Address: 1EpiVax, University of Rhode Island, Providence, RI, USA and 2University of Freiburg, Freiburg, Germany
* Corresponding author    
Background
We continue to make progress on a multi-epitope, cross-
clade GAIA HIV vaccine [De Groot, Vaccine, 2008, 26:
3059–71]. New evidence from elite controllers supports
our original hypothesis that multiple, highly conserved T-
cell epitopes in a single HIV vaccine construct will better
control HIV infection [Davenport, Immunol Rev., April
2007; Kong, J Virol., March 2009]. We believe that T cell-
mediated vaccines constructed from highly cross-con-
served HIV Th and CTL epitopes will succeed with the
benefit of advances in the adjuvant, formulation and
delivery areas that will inform better vaccine construction.
We have performed several recent studies that also sup-
port this hypothesis.
Methods
EpiVax' suite of vaccine design tools have enabled effec-
tive selection of cross-clade conserved HIV epitopes, and
the delivery of those epitopes in properly designed con-
structs are important steps toward production of an effec-
tive vaccine.
Results
We provide three recent T-cell directed vaccination suc-
cesses that illustrate the use of such vaccine design tools in
preclinical challenge models and their potential for devel-
opment of a protective T cell-directed HIV vaccine: (i)
HLA class II conserved T-cell epitopes derived from the
variola genome fully protected HLA DR3 transgenic mice
from 10× LD50 vaccinia challenge without B cell priming;
(ii) HLA class I and class II F. tularensis T-cell epitopes
extended the mean time-to-death of A2/DR1 transgenic
mice challenged with 20× LD50 attenuated F. holarctica
by 53%; and, (iii) HLA class II T-cell epitopes stimulated
long-lived immune responses and cleared infection in a
p27 knockout mouse model of H. pylori infection.
Conclusion
The lessons learned from these recent studies hold prom-
ise for design of a globally relevant HIV vaccine using
cross-clade HLA class I and class II T-cell epitopes, con-
served over time and geography, that will be broadly
immunogenic in the HLA diverse world population.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P308 doi:10.1186/1742-4690-6-S3-P308
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P308
© 2009 De Groot et al; licensee BioMed Central Ltd. 


P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success

De Groot, Anne S

Moise, Leonard

Desrosiers, J.

Weber, C.

Martin, W.

DigitalCommons@URI

University of Rhode IslandDigitalCommons@URIInstitute for Immunology and Informatics FacultyPublications Institute for Immunology and Informatics (iCubed)2009P17-26. Effective Design of T-Cell Driven VaccinesApplied to the GAIA HIV Vaccine: Advances inVaccine Design Based on Current PreclinicalSuccessAnne S. De GrootUniversity of Rhode Island, annied@uri.eduLeonard MoiseUniversity of Rhode Island, lmoise@uri.eduSee next page for additional authorsFollow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubsTerms of UseAll rights reserved under copyright.This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It hasbeen accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator ofDigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.Citation/Publisher Attribution© 2009 De Groot et al; licensee BioMed Central Ltd.AuthorsAnne S. De Groot, Leonard Moise, J. Desrosiers, C. Weber, and W. MartinThis article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/37BioMed CentralPage 1 of 1(page number not for citation purposes)RetrovirologyOpen AccessPoster presentationP17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical successAS De Groot*1, L Moise1, J Desrosiers1, C Weber2 and W Martin1Address: 1EpiVax, University of Rhode Island, Providence, RI, USA and 2University of Freiburg, Freiburg, Germany* Corresponding author    BackgroundWe continue to make progress on a multi-epitope, cross-clade GAIA HIV vaccine [De Groot, Vaccine, 2008, 26:3059–71]. New evidence from elite controllers supportsour original hypothesis that multiple, highly conserved T-cell epitopes in a single HIV vaccine construct will bettercontrol HIV infection [Davenport, Immunol Rev., April2007; Kong, J Virol., March 2009]. We believe that T cell-mediated vaccines constructed from highly cross-con-served HIV Th and CTL epitopes will succeed with thebenefit of advances in the adjuvant, formulation anddelivery areas that will inform better vaccine construction.We have performed several recent studies that also sup-port this hypothesis.MethodsEpiVax' suite of vaccine design tools have enabled effec-tive selection of cross-clade conserved HIV epitopes, andthe delivery of those epitopes in properly designed con-structs are important steps toward production of an effec-tive vaccine.ResultsWe provide three recent T-cell directed vaccination suc-cesses that illustrate the use of such vaccine design tools inpreclinical challenge models and their potential for devel-opment of a protective T cell-directed HIV vaccine: (i)HLA class II conserved T-cell epitopes derived from thevariola genome fully protected HLA DR3 transgenic micefrom 10× LD50 vaccinia challenge without B cell priming;(ii) HLA class I and class II F. tularensis T-cell epitopesextended the mean time-to-death of A2/DR1 transgenicmice challenged with 20× LD50 attenuated F. holarcticaby 53%; and, (iii) HLA class II T-cell epitopes stimulatedlong-lived immune responses and cleared infection in ap27 knockout mouse model of H. pylori infection.ConclusionThe lessons learned from these recent studies hold prom-ise for design of a globally relevant HIV vaccine usingcross-clade HLA class I and class II T-cell epitopes, con-served over time and geography, that will be broadlyimmunogenic in the HLA diverse world population.from AIDS Vaccine 2009Paris, France. 19–22 October 2009Published: 22 October 2009Retrovirology 2009, 6(Suppl 3):P308 doi:10.1186/1742-4690-6-S3-P308<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>This abstract is available from: http://www.retrovirology.com/content/6/S3/P308© 2009 De Groot et al; licensee BioMed Central Ltd. 

P17-26. Effective Design of T-Cell Driven Vaccines Applied to the GAIA HIV Vaccine: Advances in Vaccine Design Based on Current Preclinical Success

https://digitalcommons.uri.edu/cgi/viewcontent.cgi?article=1036&amp;context=immunology_facpubs

P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

DigitalCommons@URI